Edition:
India

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

22.80USD
18 Apr 2019
Change (% chg)

$0.27 (+1.20%)
Prev Close
$22.53
Open
$22.52
Day's High
$23.04
Day's Low
$21.75
Volume
65,990
Avg. Vol
73,026
52-wk High
$35.48
52-wk Low
$21.16

Select another date:

Sat, Nov 10 2018

Mylan and Theravance's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

UPDATE 2-Mylan and Theravance's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Mylan and Theravance Biopharma's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Select another date: